Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade

Rhea-AI Filing Summary

Relay Therapeutics’ President of R&D, Donald A. Bergstrom, reported an open-market sale of 8,660 shares of common stock at a weighted average price of $18.71 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, he directly holds 409,897 shares, including 15,037 shares underlying restricted stock units.

Insights

Insider transactions analyst

Small, pre-planned insider sale with large remaining stake.

Relay Therapeutics’ President of R&D, Donald A. Bergstrom, sold 8,660 common shares in an open-market transaction at a weighted average price of $18.71 per share. The filing states this was done under a Rule 10b5-1 trading plan adopted on October 30, 2025, indicating it was pre-scheduled.

After the sale, Bergstrom directly owns 409,897 shares, which includes 15,037 shares underlying restricted stock units. The shares sold represent only a small fraction of his reported holdings, suggesting a routine liquidity event rather than a major shift in exposure based on this filing alone.

Insider Trade Summary 10b5-1

Net Seller: 8,660 shares ($162,029)

Net Sell 1 txn

Insider Bergstrom Donald A

Role President, R&D

Sold 8,660 shs ($162K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,660	$18.71	$162K

Holdings After Transaction: Common Stock — 409,897 shares (Direct, null)

Footnotes (1)

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. This transaction was executed in multiple trades at prices ranging from $18.45 to $19.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 15,037 shares underlying restricted stock units.

Key Figures

Shares sold: 8,660 shares Weighted average sale price: $18.71 per share Post-transaction holdings: 409,897 shares +2 more

5 metrics

Shares sold 8,660 shares Open-market sale on July 6, 2026

Weighted average sale price $18.71 per share Common stock sale

Post-transaction holdings 409,897 shares Direct ownership after sale

RSUs included in holdings 15,037 shares Shares underlying restricted stock units

Trade price range $18.45–$19.36 per share Multiple trades within reported transaction

Key Terms

Rule 10b5-1 trading plan, restricted stock units, open-market sale, weighted average sale price

4 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 15,037 shares underlying restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/08/2026 - 05:11 PM Accepted by SEC EDGAR 07/08/2026 - 05:11 PM Learn about SEC filing dates

FAQ

What insider transaction did Relay Therapeutics (RLAY) report for Donald A. Bergstrom?

Relay Therapeutics reported that President of R&D Donald A. Bergstrom sold 8,660 shares of common stock in an open-market transaction. The weighted average sale price was $18.71 per share, with trades executed between $18.45 and $19.36 according to the filing footnote.

Was the Relay Therapeutics (RLAY) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan adopted by Donald A. Bergstrom on October 30, 2025. Such plans are pre-arranged trading programs, indicating the timing of this transaction was scheduled in advance rather than discretionary.

How many Relay Therapeutics (RLAY) shares does Donald A. Bergstrom hold after this sale?

After the reported sale, Donald A. Bergstrom directly holds 409,897 shares of Relay Therapeutics common stock. This total includes 15,037 shares underlying restricted stock units, as disclosed in the footnotes, providing context for his remaining equity position with the company.

What price range did the Relay Therapeutics (RLAY) insider sale cover?

The transaction was executed in multiple trades at prices ranging from $18.45 to $19.36 per share. The Form 4 reports a weighted average sale price of $18.71 per share, and notes that detailed trade breakdowns are available upon request from the reporting person.

What role does Donald A. Bergstrom hold at Relay Therapeutics (RLAY)?

Donald A. Bergstrom is identified in the filing as President, R&D of Relay Therapeutics. His position as a senior executive makes his equity transactions reportable under Section 16 rules, which require timely disclosure of trades in the company’s securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bergstrom Donald A

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		8,660	D	$18.71(2)	409,897(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $18.45 to $19.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 15,037 shares underlying restricted stock units.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)